Interventional cardiology

Thubrikar Aortic Valve Announces Clinical Success of the New Precision 2™ Delivery Catheter

Retrieved on: 
Montag, Mai 6, 2024
Research, Surgery, Medical Devices, Venture Capital, Clinical Trials, Professional Services, Cardiology, Health, Science, TAVI, Interventional cardiology, Mathematical optimization, MD, NYU Langone Health, University Medical Center, Fluoroscopy, Patient, Aortic valve, Physician, TAV, Medical device

Thubrikar Aortic Valve, Inc. today announced successful results in the first two patients implanted with the Optimum Transcatheter Aortic Valve (Optimum TAV™) using the new Precision 2™ Delivery Catheter.

Key Points: 
  • Thubrikar Aortic Valve, Inc. today announced successful results in the first two patients implanted with the Optimum Transcatheter Aortic Valve (Optimum TAV™) using the new Precision 2™ Delivery Catheter.
  • “The first two implants with the 2nd-generation delivery catheter could not be easier or more effective.
  • Due to the innovative catheter design and the Optimum TAV’s short frame, the valve reorients as it is deployed resulting in automatic axial alignment with the native valve.
  • Dr. Mano Thubrikar, the Company’s Founder and President, stated, “The Optimum TAVI System offers patients a more durable transcatheter valve and physicians a more user-friendly delivery catheter.

Vivasure Medical Announces First Large Hole Venous Patient Treated with PerQseal Elite Vascular Closure System

Retrieved on: 
Montag, April 15, 2024
Biotechnology, Surgery, Medical Devices, Health, Cardiology, Collagen, Interventional cardiology, TMVR, Safety, Patient, Medicine, Suture, Elite, Medical imaging

Vivasure Medical ®, a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced it has treated the first large bore venous patient with the PerQseal® Elite vascular closure system, a sutureless and fully bioresorbable large-bore vessel closure device.

Key Points: 
  • Vivasure Medical ®, a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced it has treated the first large bore venous patient with the PerQseal® Elite vascular closure system, a sutureless and fully bioresorbable large-bore vessel closure device.
  • Leveraging Vivasure Medical’s PerQseal technology, the PerQseal Elite vascular closure system is designed exclusively for sutureless and fully absorbable large-bore venous vessel closure following percutaneous cardiovascular procedures, such as transcatheter mitral valve repair or replacement (TMVR), transcatheter tricuspid valve repair or replacement (TTVR) and leadless pacemaker implants.
  • “Current venous closure methods are not indicated for large hole venous access applications like Transcatheter Edge-to-Edge repair (TEER), TMVR and TTVR.
  • “We’re encouraged by the early progress we’ve seen in clinical studies of the Elite vascular closure system to address this unmet need.

FastWave Medical Extends Intellectual Property Portfolio with the Issuance of its Utility Patent for Novel Laser-IVL Technology

Retrieved on: 
Dienstag, April 16, 2024
Interventional cardiology, Mortality, Emory Healthcare, IP, Calcium, IVL, Cardiology, Patent, Patient, Physician, Intellectual property, Associate, Artery, Disease, Pharmaceutical industry

MINNEAPOLIS, April 16, 2024 /PRNewswire-PRWeb/ -- FastWave Medical, a pre-revenue medical device company developing advanced intravascular lithotripsy (IVL) technology, proudly announces the issuance of its fourth utility patent by the United States Patent and Trademark Office (USPTO). This significant milestone further strengthens the company's intellectual property foundation to advance its next-generation laser-IVL platform. This innovative technology is designed to provide physicians with more options to effectively treat calcific artery disease, offering durable and fast energy delivery, enhanced sonic output, and a high-performing catheter to navigate complex arterial anatomy.

Key Points: 
  • Fast-moving medical device startup continues to fortify its intellectual property protection with the company's latest patent for a novel laser-IVL system from USPTO.
  • MINNEAPOLIS, April 16, 2024 /PRNewswire-PRWeb/ -- FastWave Medical, a pre-revenue medical device company developing advanced intravascular lithotripsy (IVL) technology , proudly announces the issuance of its fourth utility patent by the United States Patent and Trademark Office (USPTO).
  • This significant milestone further strengthens the company's intellectual property foundation to advance its next-generation laser-IVL platform.
  • "FastWave's novel approach has enormous potential to leapfrog today's IVL technology with durable, fast, and consistent laser energy.

Study of NFL Alumni Cohort Finds Majority Suffer From Heart Disease Without Knowing It

Retrieved on: 
Sonntag, April 7, 2024
Health, Sports, Football, Other Health, Other Science, Research, Science, Blood pressure, TTE, FACC, African Americans, Prevalence, Aortic stenosis, National Football League, Patient, Education, Ageing, Journal, History, MD, City, Male, American College, TAVR, EKG, AFL, Interventional cardiology, Alumni association, NFL, National Football League Alumni, Hypertension, Pharmaceutical industry

Edwards Lifesciences (NYSE: EW) announced the release of data from the HUDDLE study that examined the prevalence of heart disease and associated risk factors among members of the National Football League (NFL) Alumni Association and their families.

Key Points: 
  • Edwards Lifesciences (NYSE: EW) announced the release of data from the HUDDLE study that examined the prevalence of heart disease and associated risk factors among members of the National Football League (NFL) Alumni Association and their families.
  • Results of the HUDDLE study indicated that the prevalence of hypertension in the 498 screened participants was 83.8%, though only about half (46.5%) self-reported a history of hypertension.
  • Conducted across eight U.S. cities in cooperation with NFL Alumni Health, a subsidiary of the NFL Alumni Association, HUDDLE was a cross sectional study of NFL alumni and their family members aged 50 years and above.
  • Study participants self-reported their medical histories and participated in heart health education and screenings that included blood pressure, electrocardiogram (EKG) and echocardiogram.

ConKay Medical Systems Raises $1.8M in Oversubscribed Seed Funding Round

Retrieved on: 
Montag, März 18, 2024
Health Technology, Health, Medical Devices, Cardiology, Tricuspid valve, Trust, Patient, Circulant matrix, University, Section, Interventional cardiology

ConKay Medical Systems, a medtech start-up company developing a unique device for treating patients suffering from valvular regurgitation, has closed an oversubscribed $1.8M seed round.

Key Points: 
  • ConKay Medical Systems, a medtech start-up company developing a unique device for treating patients suffering from valvular regurgitation, has closed an oversubscribed $1.8M seed round.
  • Multiple investment funds participated in the round including Unorthodox Ventures, SCP Ventures, WS Investment Company, and individual angel investors.
  • “ConKay’s innovative technology addresses a significant unmet need experienced by tens of millions of patients,” said Unorthodox Ventures Founder Carey Smith.
  • Albert Yuan, Founder and CEO of ConKay Medical, shared, "Millions of Tricuspid Regurgitation patients worldwide are currently left with no medical options and at ConKay, our mission is to help patients live longer lives with their loved ones.

PulseCath Achieves MDR CE Certification for iVAC 2L, Paving the Way for Complex High-Risk Percutaneous Coronary Interventions

Retrieved on: 
Montag, März 11, 2024
Certification, Aorta, MDD, Risk, Patient, Femoral artery, Medical device, Diastole, MCS, Interventional cardiology, MDR, Pump, PCI, Safety, Blood, Medical device regulation

The MDR CE certification signifies PulseCath's commitment to the highest standards of quality and safety in medical devices.

Key Points: 
  • The MDR CE certification signifies PulseCath's commitment to the highest standards of quality and safety in medical devices.
  • The iVAC 2L System is a percutaneous Mechanical Circulatory Support (MCS) device.
  • It can be used to facilitate high-risk Percutaneous Coronary Interventions (PCIs).
  • iVAC 2L represents a leap forward in complex High-Risk PCI's, and we are eager to make this transformative device available to healthcare providers and patients worldwide."

PulseCath Achieves MDR CE Certification for iVAC 2L, Paving the Way for Complex High-Risk Percutaneous Coronary Interventions

Retrieved on: 
Montag, März 11, 2024
Certification, Aorta, MDD, Risk, Patient, Femoral artery, Medical device, Diastole, MCS, Interventional cardiology, MDR, Pump, PCI, Safety, Blood, Medical device regulation

The MDR CE certification signifies PulseCath's commitment to the highest standards of quality and safety in medical devices.

Key Points: 
  • The MDR CE certification signifies PulseCath's commitment to the highest standards of quality and safety in medical devices.
  • The iVAC 2L System is a percutaneous Mechanical Circulatory Support (MCS) device.
  • It can be used to facilitate high-risk Percutaneous Coronary Interventions (PCIs).
  • iVAC 2L represents a leap forward in complex High-Risk PCI's, and we are eager to make this transformative device available to healthcare providers and patients worldwide."

Affluent Medical : Excellent valve performance at 1 year follow up and rising recognition of Epygon biomimetic mitral valve.

Retrieved on: 
Mittwoch, März 13, 2024
Mitral regurgitation, Ticker, Aix-en-Provence, Doctor of Philosophy, MD, Overalls, Physiology, Hospital, Minerva, Risk, Tricuspid valve, Mayo Clinic, Clinical professor, Death, American College, Medtech, Mitral valve, Patient, Interventional cardiology

Affluent Medical : Excellent valve performance at 1 year follow up and rising recognition of Epygon biomimetic mitral valve.

Key Points: 
  • Affluent Medical : Excellent valve performance at 1 year follow up and rising recognition of Epygon biomimetic mitral valve.
  • The article summarizes the procedure and the follow up at 6 months, which showed continued good prosthetic performance.
  • Examination through a transesophageal echocardiogram revealed excellent valve performance, with neither mitral regurgitation nor paravalvular leak.
  • Mitral valve regurgitation is a serious and potentially fatal disease affecting 2% of the world's population, or approximately 160 million people.

Radcliffe Group Selects Springer Healthcare for Reprint Sales to Pharmaceutical Industry

Retrieved on: 
Dienstag, März 5, 2024
AER, Interventional cardiology, Arrhythmia, Partnership, Life, CFR, Content, ECR, USC, Patient, Journal, Knowledge, Science, Springer Nature

BOURNE END, England, March 5, 2024 /PRNewswire-PRWeb/ -- Today Radcliffe Group, which brings the latest and best science, information, and knowledge to cardiovascular clinicians around the world, announced it has chosen Springer Healthcare in an exclusive deal to handle its reprints to buyers in the pharmaceutical industry. The deal was facilitated by content licensing specialist MEI Global, LLC (MEIG), a leader in helping publishers create new revenue streams through strategic third-party partnerships.

Key Points: 
  • BOURNE END, England, March 5, 2024 /PRNewswire-PRWeb/ -- Today Radcliffe Group, which brings the latest and best science, information, and knowledge to cardiovascular clinicians around the world, announced it has chosen Springer Healthcare in an exclusive deal to handle its reprints to buyers in the pharmaceutical industry.
  • Jonathan McKenna, Managing Director of Radcliffe Cardiology, says "Radcliffe strives to equip healthcare professionals with the skills and practical insights they need to do their best for patients by bringing the world's cardiovascular knowledge to life.
  • We are excited about partnering with Springer Healthcare and leveraging their established connections in the pharmaceutical market to aide us in that goal."
  • "A number of discussions and negotiations for complementary redistribution deals are also underway, and we're excited to help Radcliffe expand the audience for this powerful medical research."

Boston Scientific Receives FDA Approval for the AGENT™ Drug-Coated Balloon

Retrieved on: 
Freitag, März 1, 2024
Boston Scientific, Diabetes, Obstruction, DCB, Interventional cardiology, Physician, FDA, ISR, Quality of life, Food, Restenosis, Find, BSX, IDE, Plaque, Radiation, Risk, Food and Drug Administration, Patient, TLF, Coronary artery disease, Pharmaceutical industry

MARLBOROUGH, Mass., March 1, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Food and Drug Administration (FDA) approval for the AGENT™ Drug-Coated Balloon (DCB), which is indicated to treat coronary in-stent restenosis (ISR) in patients with coronary artery disease. ISR is the obstruction or narrowing of a stented vessel by plaque or scar tissue.

Key Points: 
  • First coronary drug-coated balloon in U.S. provides safe, effective alternative to treat coronary in-stent restenosis and reduce risk of reoccurrence
    MARLBOROUGH, Mass., March 1, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Food and Drug Administration (FDA) approval for the AGENT™ Drug-Coated Balloon (DCB), which is indicated to treat coronary in-stent restenosis (ISR) in patients with coronary artery disease.
  • ISR is the obstruction or narrowing of a stented vessel by plaque or scar tissue.
  • Experience the full interactive Multichannel News Release here: https://www.multivu.com/players/English/9029352-boston-scientific-fda-ap...
    "With more than 100,000 patients treated globally to date in both clinical and commercial settings, we are very pleased to introduce this proven therapy as the first drug-coated coronary balloon in the U.S," said Lance Bates, president, Interventional Cardiology Therapies, Boston Scientific.
  • Boston Scientific plans to launch the technology in the U.S. in the coming months.